Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation

Ruiz-Nodar, Juan M.; Marı́n, Francisco; Hurtado, José Antonio; Valencia, José; Pinar, Eduardo; Pineda, Javier; Gimeno, Juan R.; Sogorb, Francisco; Valdés, Mariano; Lip, Gregory Y.H.

doi:10.1016/j.jacc.2007.11.035

Cited by 250 publications

(146 citation statements)

References 24 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…LEKAMI PRZECIWZAKRZEPOWYMI I LEKAMI PRZECIWPŁYTKOWYMI Przebyty zawał serca stwierdza się u około 15% pacjentów z AF uczestniczących we współczesnych próbach klinicznych [513] i rejestrach [514][515][516]. U 5-15% pacjentów z AF w którymś momencie ich życia będzie konieczne stentowanie.…”

Section: Skojarzona Terapia Doustnymiunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,339

4,206

View full text Add to dashboard Cite

Section: Skojarzona Terapia Doustnymiunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,339

4,206

View full text Add to dashboard Cite

“…Approximately 15% of AF patients in contemporary trials 513 and registries 514 -516 have a history of myocardial infarction. Between 5 -15% of AF patients will require stenting at some point in their lives.…”

Section: Combination Therapy With Oral Anticoagulants and Antiplateletsmentioning

confidence: 99%

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof¹,

Benussi²,

Kotecha³

et al. 2016

Eur J Cardiothorac Surg

899

625

View full text Add to dashboard Cite

“…From 625 initial citations, 16 eligible studies including a total of 9185 patients were identified in the present meta‐analysis,4, 5, 6, 7, 12, 14, 15, 19, 20, 21, 22, 23, 24, 25, 26, 27 with 5680 patients in the triple therapy group and 3505 in the dual therapy group (Figure 1). …”

Section: Resultsmentioning

confidence: 99%

“…Finally, 12 studies were identified in the DAPT subgroup,4, 5, 6, 7, 19, 20, 21, 22, 23, 24, 25, 26 with the other 4 studies included in the OAC/C subgroup 12, 14, 15, 27…”

Section: Resultsmentioning

confidence: 99%

Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta‐analysis of 16 Clinical Trials and 9185 Patients

Gao

Chen

Fan

et al. 2015

Clinical Cardiology

View full text Add to dashboard Cite

The optimal antithrombotic regimen remains controversial in patients taking oral anticoagulation (OAC) undergoing coronary stenting. This study sought to compare efficacy and safety outcomes of triple therapy (OAC, aspirin, and clopidogrel) vs dual therapy (clopidogrel with aspirin or OAC) in these patients. We hypothesize OAC plus clopidogrel could be the optimal regimen for patients with indications for OAC receiving stent implantation. Medline, the Cochrane Library, and other Internet sources were searched for clinical trials comparing the efficacy and safety of triple vs dual therapy for patients taking OAC after coronary stenting. Sixteen eligible trials including 9185 patients were identified. The risks of major adverse cardiac events (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 0.82‐1.39, P = 0.65), all‐cause mortality (OR: 0.98, 95% CI: 0.76‐1.27, P = 0.89), myocardial infarction (OR: 1.01, 95% CI: 0.77‐1.31, P = 0.97), and stent thrombosis (OR: 0.91, 95% CI: 0.49‐1.69, P = 0.75) were similar between triple and dual therapy. Compared with dual therapy, triple therapy was associated with a reduced risk of ischemic stroke (OR: 0.57, 95% CI: 0.35‐0.94, P = 0.03) but with higher major bleeding (OR: 1.52, 95% CI: 1.11‐2.10, P = 0.01) and minor bleeding (OR: 1.59, 95% CI: 1.05‐2.42, P = 0.03). Subgroup analysis indicated there were similar ischemic stroke and major bleeding outcomes between triple therapy and therapy with OAC plus clopidogrel. Treatment with OAC and clopidogrel was associated with similar efficacy and safety outcomes compared with triple therapy. Triple therapy could be replaced by OAC plus clopidogrel without any concern about additional risk of thrombotic events.

show abstract

Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation

Abstract: Patients with AF undergoing PCI with stenting represent a high-risk population because of age, comorbidities, and presence of stroke risk factors. These patients have a high mortality and MACE rate, which is reduced by anticoagulation therapy.

Cited by 250 publications

References 24 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta‐analysis of 16 Clinical Trials and 9185 Patients

Contact Info

Product

Resources

About